Chengdu and Wuxi State-Owned Investors Inject RMB 260 Million into AI-Powered Cell Therapy Biotech Ruijian Medicine Ahead of IPO Filing

Jul 03, 2026 18:15 CST Updated 18:15

iRegene Therapeutics

Cell Therapy Product Developer

On July 2, iRegene Therapeutics announced the completion of its C+ round financing, raising RMB 260 million.

This round of financing is led byLed by Chengdu Sci-Tech Innovation Investment, with participation from CSC Financial Capital, Wuxi Venture Capital, Dingtai Xing, Xinjiye, and Hony Capitalco-invested by institutions such as iRegene Therapeutics, existing shareholdersYuanxi Haihe, Jinsha RiveriRegene Therapeutics continues to increase its investment in Runpu Yuanfeng.

This is alreadyiRegene Therapeutics Completes Two Rounds of Financing Within One MonthIn early June 2026,iRegene Therapeutics Completes RMB 210 Million FinancingCo-led by Photosynthesis Venture Capital and Xingze Capital.

iRegene Therapeutics was founded in 2017, with its headquarters located in Chengdu, Sichuan. The core team hails from the University of Cambridge in the United Kingdom andThe Roslin Institute, UK.

The company focuses on small-molecule chemical transcriptional regulation of iPSCs and has established the first"AI + Chemical Induction"cell-based drug development platform, with multiple products in the fields of neurodegenerative diseases and ophthalmology.

iRegene Therapeutics' core pipeline consists of independently developedNouvNeu001 Injection, as the world’s first iPSC-derived universal dopamine precursor cell therapy product to enter clinical development, for the treatment of Parkinson’s disease.

On August 15, 2025, the NouvNeu001 injection was granted by the FDAFast Track Designation (FTD) Qualification, and approved to expand the scope of application,It is the world’s first Fast Track Designation (FTD) for a universal iPSC-derived cell therapy product for Parkinson’s disease.In addition to receiving a Special Exemption from the FDA in March 2024, this product has further secured support through the FDA’s Fast Track Designation (FTD) pathway.

Currently, the drug has completed full enrollment and dosing for its Phase II clinical trial in China, as well as administered the first dose in its US Phase II clinical trial.

Furthermore, NouvNeu004, developed by the Company for multiple system atrophy with predominant parkinsonism (MSA-P), has entered simultaneous clinical development in China and the United States. This further validates the scalability of iRegene Therapeutics’ AI platform in identifying common pathological mechanisms across different neurological disorders, discovering functional cell regulatory pathways, and generating candidate products.

In the field of ophthalmic diseases, the company has structured its NouvSight pipeline portfolio around irreversible visual function impairment. The successful advancement of this platform is expected to further expand its application boundaries in ophthalmology.

The formation of iRegene Therapeutics’ product portfolio signifies that the company is no longer merely a single-pipeline entity, but is evolving into a platform-based biotech driven by an AI-powered foundational platform, capable of continuously generating innovative cell therapy products.

—The End—

Recommended Reading